Clinical trials
Liver Carcinoma clinical trials
Below are recruiting liver carcinoma clinical trials, each written for real people, not researchers. We’re tracking 177 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06434753RecruitingPhase 3
Zinc supplements for stable advanced liver disease
This trial tests whether taking zinc supplements can improve the outlook for people with a certain type of advanced liver disease that is still stable (no major complications). If you have compensated advanced chronic liver disease and meet the criteria, you might be able to join.
BarcelonaAges 18–80 - NCT07224724Recruiting
Exosome liquid biopsy for colorectal cancer spread
This study uses a blood test to detect if colorectal cancer that has spread to the liver has also spread to other parts of the body. It may help doctors better understand how the cancer is moving and guide treatment decisions.
Duarte, CaliforniaAges 18 years+ - NCT07298577Enrolling by invitation
Using blood test and ultrasound to find early liver cancer in Asia
This study tests whether adding a simple blood test (GAAD score) to a routine liver ultrasound can find early-stage liver cancer sooner in people with chronic liver conditions. It aims to improve detection in Asian populations at risk.
Bangkok Noi, BangkokAges 18 years+ - NCT06555133RecruitingPhase 2
Study of Y-90, capecitabine, and atezolizumab for advanced colorectal cancer
This trial tests a combination of targeted radiation (Y-90), chemotherapy (capecitabine), and immunotherapy (atezolizumab) for people with colorectal cancer that has spread mainly to the liver and is no longer responding to at least two prior treatments. The goal is to see if this combination can shrink tumors or slow the disease.
Providence, Rhode IslandAges 18 years+ - NCT05541601Recruiting
Study to detect liver cancer early in people with cirrhosis
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
Oxford, OxfordshireAges 18–100 - NCT06184152Recruiting
Comparing two scans to find liver cancer early
This trial compares two types of imaging scans (CEUS and AMRI) to see which one is better at finding liver cancer (HCC) in patients who have an unclear spot on their liver (an indeterminate nodule). It is for people with cirrhosis who have at least one such nodule but no confirmed liver cancer yet.
Ann Arbor, MichiganAges 18 years+ - NCT06383520RecruitingEarly Phase 1
PET imaging for GPC3 in liver cancer
This study tests a new PET imaging method that targets GPC3, a protein often found in liver cancer cells. It may help doctors see and understand liver cancer better, especially in people with newly diagnosed or recurrent disease.
Wuhan, HubeiAges 18–65 - NCT06518434RecruitingPhase 2
Cannabis oil for advanced liver cancer study
This study tests if cannabis oil can help people with advanced liver cancer that cannot be treated with standard therapies. It is a small pilot study to see if the oil is safe and may improve symptoms or quality of life.
GroningenAges 18 years+ - NCT06687941RecruitingPhase 1
Trial of AST-201 for GPC3-positive advanced solid tumors
This trial tests a new drug called AST-201 for people with advanced solid tumors that have a specific protein (GPC3). The study aims to see how safe and well-tolerated the drug is, and how the body processes it.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT03942328RecruitingPhase 1/Phase 2
Immune cell vaccine plus checkpoint treatment after liver radiation
This trial tests a combination of a personalized immune cell treatment (made from your own cells) and a pneumococcal vaccine along with an “immune checkpoint” drug after high-dose radiation for certain unresectable liver cancers. The goal is to help your immune system better attack the cancer and to see how safe and effective this approach is.
Rochester, MinnesotaAges 18 years+ - NCT07282184RecruitingPhase 1/Phase 2
Liver cancer risk prediction and treatment study
This trial uses a computer model to predict if your liver cancer might come back aggressively after surgery. If you are at high risk, you may receive additional treatment before surgery to lower that risk.
Wuhan, HubeiAges 18–75 - NCT06060769Recruiting
MRI risk assessment for liver cancer in chronic liver disease
This study uses special MRI scans to better predict liver cancer risk in people with chronic liver disease. It may help doctors identify high-risk patients earlier and improve monitoring.
Zhuhai, GuangdongAges 18 years+ - NCT04510740Recruiting
Liver cancer registry study to improve future care
This study records information about people with liver cancer (hepatocellular or bile duct cancer) to help improve how care is planned and delivered. You may join a patient-experience part before or soon after starting your first main treatment.
Multiple SitesAges 18 years+ - NCT05466565Recruiting
Peginterferon antiviral treatment after liver cancer surgery
This trial studies an antiviral medicine given after surgery for liver cancer to help prevent the cancer from coming back. It focuses on people who are hepatitis B–positive (HBsAg positive) and have complete remission on follow-up checks.
Changsha, HunanAges 18–65 - NCT06990659Recruiting
Outpatient vs. Inpatient Liver Cancer Treatment Study
This study compares having your liver cancer treatment (TACE or TARE) as an outpatient versus staying in the hospital overnight. It's for people with primary liver cancer whose liver and kidney function are good enough and who can safely go home the same day with support.
AmiensAges 18 years+ - NCT07476651Recruiting
Study of a scout dose of resin microspheres for liver cancer
This trial is testing a low 'scout' dose of tiny radioactive beads (resin microspheres) given into the liver to treat liver cancer. The goal is to see if this approach is safe and helps patients with certain types of liver cancer that cannot be surgically removed.
SeoulAges 19 years+ - NCT05185505RecruitingPhase 4
Atezolizumab and bevacizumab before liver transplant for liver cancer
This trial tests giving atezolizumab plus bevacizumab before liver transplant in people with hepatocellular carcinoma (HCC) that is too advanced to be listed within the “Milan criteria,” but still transplant-eligible. The goal is to control the cancer outside the transplant period and improve transplant outcomes.
Houston, TexasAges 18 years+ - NCT06778317Recruiting
Blood test to predict liver cancer in cirrhosis patients
This trial tests if a simple blood test can help predict who with cirrhosis might develop liver cancer, so doctors can monitor and treat those patients earlier.
Vandœuvre-lès-NancyAges 18 years+ - NCT06624189Enrolling by invitation
Liver cancer screening decision support for cirrhosis patients
This trial tests a tool to help doctors and patients decide when to screen for liver cancer. It is for people with cirrhosis who have not had imaging in the last 6 months.
New York, New YorkAges 18 years+ - NCT07469319Recruiting
Liver cancer screening for people with cirrhosis
This study tests whether offering an ultrasound and a blood test (alpha-fetoprotein) every 6 months can help find liver cancer early in people with cirrhosis (scarred liver) caused by conditions other than hepatitis B or C. The goal is to reduce deaths from liver cancer in this group.
Aarhus, Central JutlandAges 40–79 - NCT04946773Recruiting
Deep liver testing study for cancer and non-cancer liver disease
This study looks closely at how the liver’s immune system and disease processes work in people with liver problems, including some with suspected or confirmed liver/bile duct cancer. You may also be offered a liver needle sample (FNA) if it’s safe for you.
Oxford, OxfordshireAges 18–75 - NCT07285850RecruitingPhase 2/Phase 3
Sequential treatment for advanced liver cancer with fatty liver
This trial tests a combination of two medications, bevacizumab and atezolizumab, given one after the other to treat advanced liver cancer that cannot be surgically removed. It is specifically for people whose liver cancer is linked to a fatty liver condition (MASLD). The goal is to see if this approach helps shrink tumors or control the disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07495215RecruitingPhase 1/Phase 2
Personalized mRNA vaccine plus immunotherapy for liver cancer after surgery
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) combined with a PD-1 inhibitor to prevent liver cancer from coming back after surgery. It is for people with early-stage liver cancer who have a high risk of recurrence.
Hangzhou, ZhejiangAges 18–75 - NCT03981497Recruiting
Microwave treatment for small, hard-to-remove liver and kidney tumors
This trial tests using a “microwave ablation” procedure to destroy small liver or kidney tumors when surgery isn’t an option or can’t remove everything. It may help patients avoid major surgery by targeting tumors directly with heat.
MilanAges 18 years+
Hear when a new Liver Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver carcinoma?
- Yes. Clin2 currently lists 177 recruiting liver carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.